Disclosures for "Final results of the SPECTRE study: real-world data giving an insight into the treatment of migraine patients with erenumab in Germany")
-
Dr. Gaul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Weber & Weber, Lundbeck, and Perfood. Dr. Gaul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan Pharma, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Perfood, and TEVA. Dr. Gaul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Allergan Pharma, Lilly, Novartis Pharma, Hormosan Pharma, Grünenthal, Sanofi-Aventis, and TEVA. Dr. Gaul has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Journal of Headache and Pain, Acta Neurologica Scandinavia. Dr. Gaul has received publishing royalties from a publication relating to health care. Dr. Gaul has received personal compensation in the range of $0-$499 for serving as a Honorary secretary with German Migraine and Headache Society.
-
Mirja Koch has received personal compensation for serving as an employee of Novartis.
-
Dr. Weiss has received personal compensation for serving as an employee of Novartis Pharma GmbH.